CTLA4Ig: bridging the basic immunology with clinical application.
Journal Article (Journal Article)
After a very long and windy road, in December of 2005 the FDA approved CTLA4Ig for the treatment of rheumatoid arthritis. Orencia is the first-in-class antagonist of CD28 costimulation. In this perspective, we discuss the science that led to CTLA4Ig development and the clinical challenges in bringing the drug from the bench to the bedside.
- Bluestone, JA; St Clair, EW; Turka, LA
- March 2006
Volume / Issue
- 24 / 3
Start / End Page
- 233 - 238
International Standard Serial Number (ISSN)
Digital Object Identifier (DOI)
- United States